激素难治性移植物抗宿主病的免疫病理学与基于生物学的治疗
急性移植物抗宿主病(GVHD)是异基因细胞移植后的主要危及生命的并发症之一,激素仍是一线治疗,但约半数患者会发展为激素难治性GVHD(SR-GVHD),预后极差。许多在早期1/2期试验中显示应答率的药物在SR-GVHD中未能证明生存优势,且缺乏能反映其独特病理生理的临床信息性动物模型。本文讨论新认识的细胞和分子机制,并为提高SR-GVHD治疗有效性提供新的转化机会。
要点
- 激素仍为急性GVHD一线治疗,但约半数患者发展为激素难治性GVHD。
- 早期1/2期试验中显示应答率的药物在SR-GVHD中未能证明生存优势。
- 缺乏能反映SR-GVHD独特病理生理的临床信息性动物模型。
核心结论
- 结合已建立的骨髓移植模型和近期SR-GVHD患者的人体试验知识,开始阐明抑制T细胞信号和促进组织耐受的新机制,增进了对SR-GVHD潜在生物学的理解。
研究设计与样本
- 综述,讨论新近认识的细胞和分子机制及SR-GVHD治疗的转化机会。
主要发现
- 约半数患者会发展为激素难治性GVHD(SR-GVHD),预后极差。
- 许多在早期1/2期试验中显示应答率的药物在SR-GVHD中未能证明生存优势。
- 缺乏能反映SR-GVHD独特病理生理的临床信息性动物模型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏能反映SR-GVHD独特病理生理的临床信息性动物模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute graft-versus-host disease (GVHD) is 1 of the major life-threating complications after allogeneic cell transplantation. Although steroids remain first-line treatment, roughly one-half of patients will develop steroid-refractory GVHD (SR-GVHD), which portends an extremely poor prognosis. Many agents that have shown encouraging response rates in early phase 1/2 trials for prevention and treatment have been unsuccessful in demonstrating a survival advantage when applied in the setting of SR-GVHD. The discovery of novel treatments has been further complicated by the absence of clinically informative animal models that address what may reflect a distinct pathophysiology. Nonetheless, the combined knowledge of established bone marrow transplantation models and recent human trials in SR-GVHD patients are beginning to illuminate novel mechanisms for inhibiting T-cell signaling and promoting tissue tolerance that provide an increased understanding of the underlying biology of SR-GVHD. Here, we discuss recent findings of newly appreciated cellular and molecular mechanisms and provide novel translational opportunities for advancing the effectiveness of treatment in SR-GVHD.
引用
- Toubai T, Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. Blood. 2020. PMID: 32526035. doi:10.1182/blood.2019000953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。